Our Deals

investment in

Pharmaxis Ltd.

$40,000,000

has acquired

$10,600,000

Series A Preferred Stock
Financing

has been acquired by

has been acquired by

has been acquired by

Perrigo Company

$52,257,546

Private Investment in
Public Equity (PIPE)

$25,000,000

$16,000,000

Series A Preferred Stock
Financing

Series 1 Preferred Stock
Financing of

$100,000,000

Initial Public Offering

has been acquired by

$5,700,000

License Agreement with

Menarini Group

granting rights to Priligy®
in Europe, most of Asia,
Latin America and the
Middle East

License and Asset Transfer
Agreement with

ALZA Corporation

and

Janssen Pharmaceutica, NV

for worldwide rights to
Priligy®

$3,600,000

Series C Preferred Stock
Financing

$4,750,000

Series B Preferred Stock
Financing of

$5,495,237

Series B Preferred Stock
Financing of

has been acquired by

Gaas Labs, LLC

$5,000,000

Secured Subordinated
Convertible Promissory Note
Financing

in partnership with
company management

has acquired

has acquired

$325,000,000

$3,200,000

Subordinated Convertible
Promissory Note Financing

Series A Financing of

$690,000,000

Rule 144A Offering of
1.5% Convertible Notes
Due 2019

$58,000,000

Initial Public Offering

License and Development
Agreement

has been acquired byaffiliates of

The Carlyle Group

and

Hellman & Friedman

$3,900,000,000

$10,000,000

Loan and Security Agreement

$4,500,000

Series A Preferred Stock
Financing of

$13,900,000

Series B Preferred Stock
Financing of

Series 2011 Preferred Stock
Financing